Major Shareholders Believe Lek Takeover Will Be a Win-Win Situation
Ljubljana, 21 October - Drug maker shareholders have deemed the SIT 105,000 (EUR 459) per Lek share acceptable. The Swiss bidder offered the higher price on Saturday, after negotiations with the major shareholders. These - Pension Fund Management (KAD), Restitution Fund (SOD), National Financial Fund (NFD), and management fund Triglav - signed an agreement to sell their stock in Lek at such a price, was said at Monday's press conference. The shareholders also said that Novartis would pay for the stock part in tolars and 20 percent in euros.
The rest of this news item is available to subscribers.
The news item consists of 692 characters (without spaces) or 139 words words.
Buy the news item. Price: 2 tokens; on account: 0 tokens.